RIPK3 and infection: For example, a newly developed Ripk3 inhibitor, UH15-38, can effectively and selectively block necroptosis of alveolar epithelial cells triggered by influenza A virus in vivo, improve lung inflammation, and prevent death after infection, which provides a certain reference for drug development of ALI 80.